Steady-state plasma glucose

1. Tirzepatide decreases steady-state plasma glucose in humans (41% vs 10%, p<0.0001).

   “SSPG improved significantly more with TZ vs diet (41% vs 10%, p<0.0001).”

   Human trialmatched 4 kg weight loss vs hypocaloric diet6 weeks

   Tirzepatide: Effect on Insulin Resistance and Human Fat Cells

   ADA Scientific Sessions 2026 abstract·7 Jun 2026

More on Tirzepatide

1. Steady-state plasma glucose increases QDiabetes-2018 in humans (+2.4%).

   “Among all participants, for each 30-unit increase in SSPG concentration, QDiabetes risk increased by 2.4% (P <0.001).”

   Humansfor each 30-unit increase in SSPG concentrationn = 448

   Asian Ancestry and Higher Predicted 10-Year Type 2 Diabetes Risk: Greater Insulin Resistance and Lower β-Cell Function

   ADA Scientific Sessions 2026 abstract·5 Jun 2026

More on QDiabetes-2018

1. Asian ancestry increases steady-state plasma glucose in humans (169 vs. 137 mg/dL).

   “SSPG concentration was also higher in ASN participants than in those of EUR ancestry (169 vs. 137 mg/dL; P <0.01, adjusted for age, sex, and BMI).”

   Humansn = 448

   Asian Ancestry and Higher Predicted 10-Year Type 2 Diabetes Risk: Greater Insulin Resistance and Lower β-Cell Function

   ADA Scientific Sessions 2026 abstract·5 Jun 2026

1. WDI15-120 predicts steady-state plasma glucose in humans (Pearson r = 0.77).

   “WDI15-120 predicted SSPG with LOOCV R2 =0.57 (95% CI, 0.27-0.77), Pearson r = 0.77, and Spearman{rho} = 0.74.”

   Humans16-point venous OGTT profilesplasma-serumn = 32

   The Width-Delay Index: a Glucose-Only OGTT Metric for Assessing Insulin Resistance

   medRxiv·7 Jul 2026Preprint

More on WDI15-120